摘要
目的:探讨伊伐布雷定联合常规治疗慢性心力衰竭患者的疗效与安全性。方法:90例心力衰竭患者随机分为伊伐布雷定组及常规治疗组各45例。常规治疗组给予常规基础抗心衰治疗,伊伐布雷定组在常规治疗基础上加用伊伐布雷定片5mg,bid。两组疗程均为12周。比较两组患者治疗前后心功能分级、静息心率、左心室射血分数(EF)、血浆N-末端脑钠素水平(血BNP)、6min步行试验等指标的变化,记录两组心血管死亡或因心衰恶化入院事件,评估两组安全性。结果:治疗12周后,伊伐布雷定组因心血管死亡或心衰恶化入院事件发生率明显低于常规治疗组(P<0.05),临床治疗总有效率明显高于常规治疗组(P<0.05)。治疗后,两组心率、LVEF、血BNP、6min步行试验结果等指标均较治疗前有明显改善(P<0.05),且伊伐布雷定组均优于常规治疗组(P<0.05)。伊伐布雷定组心衰发生率低于常规治疗组(P<0.05),两组不良事件发生率差异无统计学意义(P>0.05)。结论:伊伐布雷定联合常规治疗能够明显改善心衰易损期心功能、降低心血管死亡及心衰恶化入院事件发生率,改善预后,安全性较高。
Objective：To investigate the efficacy and safety of ivabradine combined with routine treatment of pa- tients with chronic heart failure. Methods ：90 patients were randomly divided into ivabradine group and routine treatment group. Routine anti-heart failure treatment was given to the patients in the routine treatment group. The patients in the iv- abradine group were treated with ivabradine 5 mg twice a day additional for 12 weeks . The changes of NYHA classifica- tion, resting heart rate, left ventricular ejection fraction （ EF）, plasma N-terminal pro-brain natriuretic peptide （ BNP）, 6- minute walk test, cardiovascular death and worsening admission events of heart failure were recorded and compared before and after treatment. The safety of the two groups were evaluated. Results：The incidence of cardiovascular death or heart failure in the ivabradine group were significantly lower than that of the routine treatment group after 12 weeks of treatment （ P 〈 0.05 ）. The total effective rate of ivabradine group was much higher than the routine treatment group （ P 〈 0.05 ）. Af- ter the treatment, the heart rate, LVEF, BNP levels, 6-minute walking distance of two groups were improved better than before （ P 〈0.05 ）, and the ivabradine group was superior to the routine treatment group. The incidence rate of heart fail- ure in ivabradine group was lower than the routine treatment group （ P 〈 0.05 ）. There had no statistical difference between the two groups on the adverse reactions （P 〉 0.05 ）. Condusion：Ivabradine combined with routine treatment could signifi- cantly improve the heart function of heart failure, reduce cardiovascular death and deterioration of heart failure admission, improve the prognosis, has high safety.
出处
《药物流行病学杂志》
CAS
2017年第9期589-592,共4页
Chinese Journal of Pharmacoepidemiology
